Evidence map›Paper›PMID 40385492›Full record

ReviewInternational journal of nanomedicine2025

Nanoemulsions Based Therapeutic Strategies: Enhancing Targeted Drug Delivery against Breast Cancer Cells.

Zahra Izadiyan, Thomas J Webster, Pooneh Kia, Katayoon Kalantari, Misni Misran, Elisa Rasouli, Zahra Maghareh Esfahan, Kamyar Shameli

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zahra IzadiyanDepartment of Chemistry, Universiti Malaya, Kuala Lumpur, Malaysia.
Thomas J WebsterSchool of Biomedical Engineering and Health Sciences, Hebei University of Technology, Tianjin, People's Republic of China.ORCID 0000-0002-2028-5969
Pooneh KiaInstitute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.ORCID 0000-0003-0449-5402
Katayoon KalantariDepartment of Chemical Engineering, Northeastern University, Boston, MA, USA.
Misni MisranDepartment of Chemistry, Universiti Malaya, Kuala Lumpur, Malaysia.
Elisa RasouliDepartment of Electrical and Electronics Engineering, Nanyang Technological University, Singapore.
Zahra Maghareh EsfahanDepartment of Chemical and Environmental Engineering, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
Kamyar ShameliSchool of Medicine, Institute of Virology, Technical University of Munich, Munich, Germany.ORCID 0000-0002-3955-4604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoemulsions (NEs), colloidal systems of nanoscale droplets (~100 nm), have emerged as transformative tools in oncology due to their high surface area-to-volume ratio, tunable physicochemical properties, and capacity for targeted drug delivery. While NEs find applications across diverse fields, their urgency in breast cancer therapy stems from critical limitations of conventional treatments, including systemic toxicity, poor bioavailability, and multidrug resistance. Unlike traditional chemotherapeutics, NEs enable precise tumor targeting via passive mechanisms (eg, enhanced permeability and retention effect) and active strategies (eg, ligand-functionalized surfaces), significantly reducing off-target effects. Their ability to encapsulate hydrophobic drugs, improve solubility, and sustain controlled release enhances therapeutic efficacy while overcoming resistance mechanisms prevalent in aggressive breast cancer subtypes, such as triple-negative and HER2-positive tumors. This review comprehensively analyzes NE formulation techniques (eg, ultrasonication, phase inversion temperature, bubble bursting), stability optimization through surfactant dynamics, and predictive modeling of droplet behavior. A focal point is their role in modulating tumor microenvironments, inducing apoptosis, and inhibiting angiogenesis in preclinical breast cancer models. By spotlighting NE-driven advancements in drug accumulation, reduced relapse rates, and adaptable combination therapies, this article underscores their potential to revolutionize oncology. Future research must prioritize clinical translation, scalability, and multifunctional NE designs to address unmet needs in precision breast cancer treatment.

Indexed as

Antineoplastic AgentsBreast NeoplasmsDrug Delivery SystemsNanoparticlesAnimalsEmulsionsFemaleHumansNanomedicineTumor MicroenvironmentAntineoplastic AgentsEmulsionsbreast cancer therapynanoemulsionsnanoscale dropletstargeted drug deliverytumor microenvironment

Identifiers

PMID40385492
PMCPMC12085896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.